The bond market has entered a financial twilight zone, and at this point, there doesn't seem to be a smooth way out.Market Insiderread more
President Donald Trump said on Twitter he was postponing a scheduled meeting with Denmark's prime minister because of her lack of interest in discussing a possible sale of...World Politicsread more
After Elon Musk touts Tesla solar on Twitter, Walmart sues the electric vehicle and clean energy company over store rooftop panels that ignited.Technologyread more
Trump said he has "been thinking about payroll taxes for a long time" — and he cautioned that "whether or not we do something now, it's not being done because of recession."Politicsread more
Secretary of State Mike Pompeo privately told business executives and free traders that the trade war could end by the 2020 election and that hurdles to an immediate agreement...2020 Electionsread more
Market bull Jeff Saut told CNBC on Tuesday that the lows are in and the market is headed "much higher."Marketsread more
Home Depot CFO Carol Tome says "consumer confidence is near record high levels" but "consumer demand could be impacted" by lingering U.S.-China trade tensions.Mad Money with Jim Cramerread more
The company's stock seesawed after the markets closed Tuesday, initially swinging up by 4% before falling by about 2%.Retailread more
VMware has become accepting of the corporate rush to the cloud. A new acquisition could help it make more revenue as companies adopt a modern approach called serverless...Technologyread more
President Donald Trump believes he has quite the bargaining chip with the European Union.Marketsread more
The United States does not have a defense against hypersonic weapons, which can travel at least five times the speed of sound, or a little more than a mile per second....Defenseread more
(Adds background, updates shares)
May 7 (Reuters) - Mylan NV missed first-quarter revenue estimates on Tuesday, hurt by lower demand for its products and manufacturing problems at its Morgantown plant, sending its shares down nearly 8 percent.
The company has been grappling with problems at its Morgantown facility in West Virginia and had last year announced discontinuation of some products and job cuts at the plant.
The U.S. Food and Drug Administration had issued a warning letter to Mylan, raising concerns such as the failure to follow the procedures for cleaning and maintaining equipment at the plant.
Only five of its top 50 and one of the top 10 gross margin generating products will be manufactured in the facility in 2019, the drugmaker said in February.
Revenue from its North America business, its biggest, fell 6 percent to $922.9 million and missed estimates of $952.43 million.
Total revenue fell 7 percent to $2.50 billion and missed estimates of $2.69 billion, according to IBES data from Refinitiv.
It was also impacted by a 14 percent drop in sales at its Europe business to $895.3 million, partly due to a stronger dollar. Analysts were expecting revenue from Europe to be $1.06 billion.
The company reported a net loss of $25 million, or 5 cents per share, in the first quarter ended March 31, compared with profit of $87.1 million, or 17 cents per share, a year earlier.
Excluding items, the company earned 82 cents per share and beat expectations of 79 cents per share.
Mylan on Tuesday did not provide an update on its decision last year to review possible strategic options.
Shares of the company were trading lower at $26.09 before the bell.
(Reporting by Saumya Sibi Joseph and Aakash Jagadeesh Babu in Bengaluru; Editing by Arun Koyyur)